|
1
|
Nahin RL, Barnes PM, Stussman BJ and Bloom
B: Costs of complementary and alternative medicine (CAM) and
frequency of visits to CAM practitioners: United States, 2007. Natl
Health Stat Report. 1–14. 2009.PubMed/NCBI
|
|
2
|
Klempner SJ and Bubley G: Complementary
and alternative medicines in prostate cancer: from bench to
bedside? Oncologist. 17:830–837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grayson M: Traditional Asian Medicine.
Nature. 480:S812011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen GQ, Zhu J, Shi XG, et al: In vitro
studies on cellular and molecular mechanisms of arsenic trioxide
(As2O3) in the treatment of acute promyelocytic leukemia: As2O3
induces NB4 cell apoptosis with downregulation of Bcl-2 expression
and modulation of PML-RAR alpha/PML proteins. Blood. 88:1052–1061.
1996.PubMed/NCBI
|
|
5
|
Cai XZ: Observation of therapeutic effect
of single-dose combined administration of Qinghaosu,
sulphomethoxine, pyrimethamine and primaquine in the treatment of
chloroquine-resistant malignant malaria (author's transl). Zhonghua
Nei Ke Za Zhi. 20:724–727. 1981.(In Chinese). PubMed/NCBI
|
|
6
|
Kang SH, Jeong SJ, Kim SH, et al:
Icariside II induces apoptosis in U937 acute myeloid leukemia
cells: role of inactivation of STAT3-related signaling. PLoS One.
7:e287062012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He R, Mott BT, Rosenthal AS, Genna DT,
Posner GH and Arav-Boger R: An artemisinin-derived dimer has highly
potent anti-cytomegalovirus (CMV) and anti-cancer activities. PLoS
One. 6:e243342011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Firestone GL and Sundar SN: Anticancer
activities of artemisinin and its bioactive derivatives. Expert Rev
Mol Med. 11:e322009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lai H, Nakase I, Lacoste E, Singh NP and
Sasaki T: Artemisinin-transferrin conjugate retards growth of
breast tumors in the rat. Anticancer Res. 29:3807–3810.
2009.PubMed/NCBI
|
|
10
|
Sun WC, Han JX, Yang WY, Deng DA and Yue
XF: Antitumor activities of 4 derivatives of artemisic acid and
artemisinin B in vitro. Zhongguo Yao Li Xue Bao. 13:541–543.
1992.(In Chinese). PubMed/NCBI
|
|
11
|
Zhang SY, Gu CH and Gao XD: A randomly
double-blinded and multicentre study of chemotherapy assisted
Yangzhengxiaoji capsule on treating primary hepatic carcinoma. J
Diffic Compl Case. 8:461–464. 2009.
|
|
12
|
Jiang WG, Ye L, Ji K, et al: Antitumour
effects of Yangzheng Xiaoji in human osteosarcoma: the pivotal role
of focal adhesion kinase signalling. Oncol Rep. 30:1405–1413.
2013.PubMed/NCBI
|
|
13
|
Ye L, Ji K, Frewer N, Ji J and Jiang WG:
Impact of Yangzheng Xiaoji on the adhesion and migration of human
cancer cells: the role of the AKT signalling pathway. Anticancer
Res. 32:2537–2543. 2012.PubMed/NCBI
|
|
14
|
Jiang WG, Ye L, Ji K, Frewer N, Ji J and
Mason MD: Inhibitory effects of Yangzheng Xiaoji on angiogenesis
and the role of the focal adhesion kinase pathway. Int J Oncol.
41:1635–1642. 2012.PubMed/NCBI
|
|
15
|
Konkimalla VB and Efferth T:
Evidence-based Chinese medicine for cancer therapy. J
Ethnopharmacol. 116:207–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
No authors listed. Astragalus
membranaceus. Monograph. Altern Med Rev. 8:72–77.
2003.PubMed/NCBI
|
|
17
|
Hofseth LJ and Wargovich MJ: Inflammation,
cancer, and targets of ginseng. J Nutr. 137 (Suppl 1):183S–185S.
2007.PubMed/NCBI
|
|
18
|
Wang GS: Medical uses of Mylabris in
ancient China and recent studies. J Ethnopharmacol. 26:147–162.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu CX, Nan KJ and Lei Y: Agents from
amphibians with anticancer properties. Anticancer Drugs.
19:931–939. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shukla Y and Kalra N: Cancer
chemoprevention with garlic and its constituents. Cancer Lett.
247:167–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuttan R, Bhanumathy P, Nirmala K and
George MC: Potential anticancer activity of turmeric (Curcuma
longa). Cancer Lett. 29:197–202. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang GS: Medical uses of mylabris in
ancient China and recent studies. J Ethnopharmacol. 26:147–162.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee TK, Johnke RM, Allison RR, O'Brien KF
and Dobbs LJ Jr: Radioprotective potential of ginseng. Mutagenesis.
20:237–243. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu D and Chen Z: The effects of
cantharidin and cantharidin derivates on tumour cells. Anticancer
Agents Med Chem. 9:392–396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshida Y, Wang MQ, Liu JN, Shan BE and
Yamashita U: Immunomodulating activity of Chinese medicinal herbs
and Oldenlandia diffusa in particular. Int J
Immunopharmacol. 19:359–370. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Y, Qian XJ, Hadley HR and Lau BH:
Phytochemicals potentiate interleukin-2 generated
lymphokine-activated killer cell cytotoxicity against murine renal
cell carcinoma. Mol Biother. 4:143–146. 1992.PubMed/NCBI
|
|
27
|
Liu J, Shi Z, Xu Z, et al: Clinical
observation on treatment of non-parvicellular carcinoma of the lung
with jin fu kang oral liquid. J Tradit Chin Med. 20:96–100.
2000.PubMed/NCBI
|
|
28
|
McCulloch M, See C, Shu XJ, et al:
Astragalus-based Chinese herbs and platinum-based chemotherapy for
advanced non-small-cell lung cancer: meta-analysis of randomized
trials. J Clin Oncol. 24:419–430. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yun TK and Choi SY: Preventive effect of
ginseng intake against various human cancers: a case-control study
on 1987 pairs. Cancer Epidemiol Biomarkers Prev. 4:401–408.
1995.PubMed/NCBI
|
|
30
|
Wu P, Dugoua JJ, Eyawo O and Mills EJ:
Traditional Chinese Medicines in the treatment of hepatocellular
cancers: a systematic review and meta-analysis. J Exp Clin Cancer
Res. 28:1122009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen M, May BH, Zhou IW, Xue CC and Zhang
AL: FOLFOX 4 combined with herbal medicine for advanced colorectal
cancer: a systematic review. Phytother Res. 28:976–991. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Z, Wen J, Zhang J, Ye M and Guo D:
Simultaneous determination of four bufadienolides in human liver by
high-performance liquid chromatography. Biomed Chromatogr.
18:318–322. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Jin Y, Xu Z, Zheng Z and Wan S:
Involvement of caspase-3 activity and survivin downregulation in
cinobufocini-induced apoptosis in A 549 cells. Exp Biol Med
(Maywood). 234:566–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang DL, Qi FH, Xu HL, et al:
Apoptosis-inducing activity of compounds screened and characterized
from cinobufacini by bioassay-guided isolation. Mol Med Rep.
3:717–722. 2010.PubMed/NCBI
|
|
35
|
Qi FH, Li AY, Lv H, et al:
Apoptosis-inducing effect of cinobufacini, Bufo bufo gargarizans
Cantor skin extract, on human hepatoma cell line BEL-7402. Drug
Discov Ther. 2:339–343. 2008.PubMed/NCBI
|
|
36
|
Qi F, Li A, Zhao L, et al: Cinobufacini,
an aqueous extract from Bufo bufo gargarizans Cantor, induces
apoptosis through a mitochondria-mediated pathway in human
hepatocellular carcinoma cells. J Ethnopharmacol. 128:654–661.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cui X, Inagaki Y, Xu H, et al:
Anti-hepatitis B virus activities of cinobufacini and its active
components bufalin and cinobufagin in HepG2.2.15 cells. Biol Pharm
Bull. 33:1728–1732. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Meng Z, Yang P, Shen Y, et al: Pilot study
of Huachansu in patients with hepatocellular carcinoma, non-small
cell lung cancer, or pancreatic cancer. Cancer. 115:5309–5318.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP
and Pan BR: Efficacy and safety of gemcitabine-oxaliplatin combined
with huachansu in patients with advanced gallbladder carcinoma.
World J Gastroenterol. 14:5210–5216. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xie X, Huang X, Li J, et al: Efficacy and
safety of Huachansu combined with chemotherapy in advanced gastric
cancer: a meta-analysis. Med Hypotheses. 81:243–250. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dong J, Su SY, Wang MY and Zhan Z: Shenqi
fuzheng, an injection concocted from Chinese medicinal herbs,
combined with platinum-based chemotherapy for advanced non-small
cell lung cancer: a systematic review. J Exp Clin Cancer Res.
29:1372010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dai Z, Wan X, Kang H, et al: Clinical
effects of shenqi fuzheng injection in the neoadjuvant chemotherapy
for local advanced breast cancer and the effects on T-lymphocyte
subsets. J Tradit Chin Med. 28:34–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang AK, He SM, Liu L, Liu JP, Wei MQ and
Zhou SF: Herbal interactions with anticancer drugs: mechanistic and
clinical considerations. Cur Med Chem. 17:1635–1678. 2010.
View Article : Google Scholar
|
|
44
|
Lu Y, Wu LQ, Dong Q and Li CS:
Experimental study on the effect of Kang-Lai-Te induced apoptosis
of human hepatoma carcinoma cell HepG2. Hepatobiliary Pancreat Dis
Int. 8:267–272. 2009.PubMed/NCBI
|
|
45
|
Guo HY, Cai Y, Yang XM, et al: Randomized
phase II trial on mitomycin-C/cisplatin +/- KLT in heavily
pretreated advanced breast cancer. Am J Chin Med. 36:665–674. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu X, Xu F, Wang G, Diao X and Li Y:
Kanglaite injection plus chemotherapy versus chemotherapy alone for
non-small cell lung cancer patients: A systematic review and
meta-analysis. Curr Ther Res Clin Exp. 69:381–411. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang QL, Xue CM, Wu SP, Li YX and Bi XJ:
Clinical observation on Yangzhengxiaoji capsule in treatment of 60
cases of moderate to severe degree atypical proliferation of
gastric mucosa. Chin J Diffic Compl Case. 7:38–39. 2008.(In
Chinese).
|
|
48
|
Xue K, Shan F and Ji J: Meta-analysis of
the safety of Yangzhengxiaoji capsule for the treatment of cancer
and precancerosis. Chin J Clin Oncol. 40:1318–1323. 2013.
|
|
49
|
Chinese Pharmacopoeia Commission, .
Pharmacopoeia of the People's Republic of China 20101. 9th.
Chemical Industry Press; Beijing: 2011
|
|
50
|
Li T, Tamada K, Abe K, et al: The
restoration of the antitumor T cell response from stress-induced
suppression using a traditional Chinese herbal medicine
Hochu-ekki-to (TJ-41: Bu-Zhong-Yi-Qi-Tang). Immunopharmacology.
43:11–21. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Niwa K, Hashimoto M, Morishita S, et al:
Preventive effects of Juzen-taiho-to on N-methyl-N-nitrosourea and
estradiol-17beta-induced endometrial carcinogenesis in mice.
Carcinogenesis. 22:587–591. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kamiyama H, Takano S, Ishikawa E, Tsuboi K
and Matsumura A: Anti-angiogenic and immunomodulatory effect of the
herbal medicine ‘Juzen-taiho-to’ on malignant glioma. Biol Pharm
Bull. 28:2111–2116. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Saiki I: A Kampo medicine ‘Juzen-taiho-to’
- prevention of malignant progression and metastasis of tumor cells
and the mechanism of action. Biol Pharm Bull. 23:677–688. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ohnishi Y, Fujii H, Hayakawa Y, et al:
Oral administration of a Kampo (Japanese herbal) medicine
Juzen-taiho-to inhibits liver metastasis of colon 26-L5 carcinoma
cells. Jpn J Cancer Res. 89:206–213. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Matsumoto M, Seya T, Kikkawa S, et al:
Interferon gamma-producing ability in blood lymphocytes of patients
with lung cancer through activation of the innate immune system by
BCG cell wall skeleton. Int Immunopharmacol. 1:1559–1569. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Miyagami M and Katayama Y: Improvement of
host-immunity by adjuvant therapy with juzen-taiho-to for patients
with brain tumors. No Shinkei Geka. 31:401–409. 2003.(In Japanese).
PubMed/NCBI
|
|
57
|
Ngo SN, Williams DB, Cobiac L and Head RJ:
Does garlic reduce risk of colorectal cancer? A systematic review.
J Nutr. 137:2264–2269. 2007.PubMed/NCBI
|
|
58
|
Sundaram SG and Milner JA: Diallyl
disulfide inhibits the proliferation of human tumor cells in
culture. Biochim Biophys Acta. 1315:15–20. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Nishino H, Iwashima A, Itakura Y, Matsuura
H and Fuwa T: Antitumor-promoting activity of garlic extracts.
Oncology. 46:277–280. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Arora A and Shukla Y: Induction of
apoptosis by diallyl sulfide in DMBA-induced mouse skin tumors.
Nutr Cancer. 44:89–94. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Arora A, Siddiqui IA and Shukla Y:
Modulation of p53 in 7,12-dimethylbenz[a]anthracene-induced skin
tumors by diallyl sulfide in Swiss albino mice. Mol Cancer Ther.
3:1459–1466. 2004.PubMed/NCBI
|
|
62
|
Kao ST, Yeh CC, Hsieh CC, et al: The
Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of
hepatoma cell lines by inducing apoptosis via G0/G1 arrest. Life
Sci. 69:1485–1496. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhu K, Fukasawa I, Furuno M, et al:
Inhibitory effects of herbal drugs on the growth of human ovarian
cancer cell lines through the induction of apoptosis. Gynecol
Oncol. 97:405–409. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Okita K, Li Q, Murakamio T and Takahashi
M: Anti-growth effects with components of Sho-saiko-to (TJ-9) on
cultured human hepatoma cells. Eur J Cancer Prev. 2:169–175. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chang WH, Chen CH and Lu FJ: Different
effects of baicalein, baicalin and wogonin on mitochondrial
function, glutathione content and cell cycle progression in human
hepatoma cell lines. Planta Med. 68:128–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chang WH, Chen CH, Gau RJ, et al: Effect
of baicalein on apoptosis of the human Hep G2 cell line was induced
by mitochondrial dysfunction. Planta Med. 68:302–306. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Motoo Y and Sawabu N: Antitumor effects of
saikosaponins, baicalin and baicalein on human hepatoma cell lines.
Cancer Lett. 86:91–95. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Matsuzaki Y, Kurokawa N, Terai S,
Matsumura Y, Kobayashi N and Okita K: Cell death induced by
baicalein in human hepatocellular carcinoma cell lines. Jpn J
Cancer Res. 87:170–177. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yano H, Mizoguchi A, Fukuda K, et al: The
herbal medicine sho-saiko-to inhibits proliferation of cancer cell
lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer
Res. 54:448–454. 1994.PubMed/NCBI
|
|
70
|
Xiao D, Herman-Antosiewicz A, Antosiewicz
J, et al: Diallyl trisulfide-induced G(2)-M phase cell cycle arrest
in human prostate cancer cells is caused by reactive oxygen
species-dependent destruction and hyperphosphorylation of Cdc 25 C.
Oncogene. 24:6256–6268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Singh SV: Impact of garlic organosulfides
on p21(H-ras) processing. J Nutr. 131:1046S–1048S. 2001.PubMed/NCBI
|
|
72
|
Bonness K, Aragon IV, Rutland B,
Ofori-Acquah S, Dean NM and Honkanen RE: Cantharidin-induced
mitotic arrest is associated with the formation of aberrant mitotic
spindles and lagging chromosomes resulting, in part, from the
suppression of PP2Aalpha. Mol Cancer Ther. 5:2727–2736. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kohno T, Matsuda E, Sasaki H and Sasaki T:
Protein-tyrosine kinase CAKbeta/PYK2 is activated by binding
Ca2+/calmodulin to FERM F2 alpha2 helix and thus forming its dimer.
Biochem J. 410:513–523. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Gilmore AP and Romer LH: Inhibition of
focal adhesion kinase (FAK) signaling in focal adhesions decreases
cell motility and proliferation. Mol Biol Cell. 7:1209–1224. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Cai J, Parr C, Watkins G, Jiang WG and
Boulton M: Decreased pigment epithelium-derived factor expression
in human breast cancer progression. Clin Cancer Res. 12:3510–3517.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Braren R, Hu H, Kim YH, Beggs HE,
Reichardt LF and Wang R: Endothelial FAK is essential for vascular
network stability, cell survival, and lamellipodial formation. J
Cell Biol. 172:151–162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ochiai K, Takita S, Eiraku T, et al:
Phosphodiesterase inhibitors. Part 3: Design, synthesis and
structure-activity relationships of dual PDE3/4-inhibitory fused
bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory
and bronchodilatory activity. Bioorg Med Chem. 20:1644–1658. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Folkman J: Angiogenesis: an organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Potente M, Gerhardt H and Carmeliet P:
Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ye B, Aponte M, Dai Y, et al: Ginkgo
biloba and ovarian cancer prevention: epidemiological and
biological evidence. Cancer Lett. 251:43–52. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Papadopoulos V, Kapsis A, Li H, et al:
Drug-induced inhibition of the peripheral-type benzodiazepine
receptor expression and cell proliferation in human breast cancer
cells. Anticancer Res. 20:2835–2847. 2000.PubMed/NCBI
|
|
82
|
Chao JC and Chu CC: Effects of Ginkgo
biloba extract on cell proliferation and cytotoxicity in human
hepatocellular carcinoma cells. World J Gastroenterol. 10:37–41.
2004.PubMed/NCBI
|
|
83
|
Kim KS, Rhee KH, Yoon JH, Lee JG, Lee JH
and Yoo JB: Ginkgo biloba extract (EGb 761) induces apoptosis by
the activation of caspase-3 in oral cavity cancer cells. Oral
Oncol. 41:383–389. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Koltermann A, Liebl J, Fürst R, Ammer H,
Vollmar AM and Zahler S: Ginkgo biloba extract EGb 761 exerts
anti-angiogenic effects via activation of tyrosine phosphatases. J
Cell Mol Med. 13:2122–2130. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Tang PM, Chan JY, Zhang DM, et al:
Pheophorbide a, an active component in Scutellaria barbata,
reverses P-glycoprotein-mediated multidrug resistance on a human
hepatoma cell line R-HepG2. Cancer Biol Ther. 6:504–509. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Goh D, Lee YH and Ong ES: Inhibitory
effects of a chemically standardized extract from Scutellaria
barbata in human colon cancer cell lines, LoVo. J Agric Food
Chem. 53:8197–8204. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Yin X, Zhou J, Jie C, Xing D and Zhang Y:
Anticancer activity and mechanism of Scutellaria barbata
extract on human lung cancer cell line A549. Life Sci.
75:2233–2244. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Perez AT, Arun B, Tripathy D, et al: A
phase 1B dose escalation trial of Scutellaria barbata
(BZL101) for patients with metastatic breast cancer. Breast Cancer
Res Treat. 120:111–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Dai ZJ, Lu WF, Gao J, et al:
Anti-angiogenic effect of the total flavonoids in Scutellaria
barbata D. Don. BMC Complement Altern Med. 13:1502013.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Shiau AL, Shen YT, Hsieh JL, Wu CL and Lee
CH: Scutellaria barbata inhibits angiogenesis through
downregulation of HIF-1 α in lung tumor. Environ Toxicol.
29:363–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Wei L, Lin J, Xu W, et al: Scutellaria
barbata D. Don inhibits tumor angiogenesis via suppression of
hedgehog pathway in a mouse model of colorectal cancer. Int J Mol
Sci. 13:9419–9430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zhao D, Qin C, Fan X, Li Y and Gu B:
Inhibitory effects of quercetin on angiogenesis in larval zebrafish
and human umbilical vein endothelial cells. Eur J Pharmacol.
723:360–367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Bellou S, Pentheroudakis G, Murphy C and
Fotsis T: Anti-angiogenesis in cancer therapy: Hercules and hydra.
Cancer Lett. 338:219–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Bosch FX and de Sanjosé S: The
epidemiology of human papillomavirus infection and cervical cancer.
Dis Markers. 23:213–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhang KH and Xie JF: Experimental study on
the treatment of oral precancerous lesion - short and long term
effect of tablet Anticancer II. Ann Acad Med Singapore. 18:528–532.
1989.PubMed/NCBI
|
|
96
|
Lu B, Xu L, Yu L and Zhang L: Extract of
radix curcumae prevents gastric cancer in rats. Digestion.
77:87–91. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Volate SR, Davenport DM, Muga SJ and
Wargovich MJ: Modulation of aberrant crypt foci and apoptosis by
dietary herbal supplements (quercetin, curcumin, silymarin, ginseng
and rutin). Carcinogenesis. 26:1450–1456. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Hou J, Lin PZ, Chen ZF, et al: Field
population-based blocking treatment of esophageal epithelia
dysplasia. World J Gastroenterol. 8:418–422. 2002.PubMed/NCBI
|
|
99
|
Ding Z, Gao F and Lin P: Long-term effect
of treating patients with precancerous lesions of the esophagus.
Zhonghua Zhong Liu Za Zhi. 21:275–277. 1999.(In Chinese).
PubMed/NCBI
|
|
100
|
Sun Z, Guan X, Li N, Liu X and Chen X:
Chemoprevention of oral cancer in animal models, and effect on
leukoplakias in human patients with ZengShengPing, a mixture of
medicinal herbs. Oral Oncol. 46:105–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Oh WK, Kantoff PW, Weinberg V, et al:
Prospective, multicenter, randomized phase II trial of the herbal
supplement, PC-SPES, and diethylstilbestrol in patients with
androgen-independent prostate cancer. J Clin Oncol. 22:3705–3712.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Olaku O, Zia F, Santana JM and White JD:
The National Cancer Institute best case series program: a summary
of cases of cancer patients treated with unconventional therapies
in India. Integr Cancer Ther. 12:385–392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zia FZ and White JD: National Cancer
Institute Best Case Series program. Integr Cancer Ther. 8:113–114.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Olaku O and White JD: Herbal therapy use
by cancer patients: a literature review on case reports. Eur J
Cancer. 47:508–514. 2011. View Article : Google Scholar : PubMed/NCBI
|
